Integrated Wealth Concepts LLC Sells 2,642 Shares of Haleon plc (NYSE:HLN)

Integrated Wealth Concepts LLC reduced its holdings in shares of Haleon plc (NYSE:HLN) by 13.0% in the third quarter, HoldingsChannel.com reports. The fund owned 17,608 shares of the company’s stock after selling 2,642 shares during the quarter. Integrated Wealth Concepts LLC’s holdings in Haleon were worth $186,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Fortitude Family Office LLC acquired a new stake in Haleon during the third quarter worth approximately $28,000. Cultivar Capital Inc. acquired a new stake in shares of Haleon during the 2nd quarter worth approximately $40,000. Prospera Private Wealth LLC bought a new stake in shares of Haleon in the 3rd quarter valued at $57,000. BOKF NA lifted its position in shares of Haleon by 68.8% during the 2nd quarter. BOKF NA now owns 6,972 shares of the company’s stock valued at $58,000 after acquiring an additional 2,842 shares during the period. Finally, Rothschild Investment LLC bought a new position in Haleon during the second quarter worth $60,000. 6.67% of the stock is owned by institutional investors.

Haleon Stock Performance

Shares of HLN stock opened at $9.76 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The firm has a fifty day simple moving average of $9.75 and a two-hundred day simple moving average of $9.51. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80. The firm has a market capitalization of $44.18 billion, a PE ratio of 28.71, a price-to-earnings-growth ratio of 2.95 and a beta of 0.28.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on HLN. UBS Group raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Morgan Stanley boosted their target price on Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Haleon has an average rating of “Buy” and an average target price of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.